Literature DB >> 21224742

Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis.

Fei-Li Zhao1, Ming Yue, Hua Yang, Tian Wang, Jiu-Hong Wu, Shu-Chuen Li.   

Abstract

OBJECTIVE: To estimate the willingness to pay (WTP) per quality-adjusted life year (QALY) ratio with the stated preference data and compare the results obtained between chronic prostatitis (CP) patients and general population (GP).
METHODS: WTP per QALY was calculated with the subjects' own health-related utility and the WTP value. Two widely used preference-based health-related quality of life instruments, EuroQol (EQ-5D) and Short Form 6D (SF-6D), were used to elicit utility for participants' own health. The monthly WTP values for moving from participants' current health to a perfect health were elicited using closed-ended iterative bidding contingent valuation method.
RESULTS: A total of 268 CP patients and 364 participants from GP completed the questionnaire. We obtained 4 WTP/QALY ratios ranging from $4700 to $7400, which is close to the lower bound of local gross domestic product per capita, a threshold proposed by World Health Organization. Nevertheless, these values were lower than other proposed thresholds and published empirical researches on diseases with mortality risk. Furthermore, the WTP/QALY ratios from the GP were significantly lower than those from the CP patients, and different determinants were associated with the within group variation identified by multiple linear regression.
CONCLUSIONS: Preference elicitation methods are acceptable and feasible in the socio-cultural context of an Asian environment and the calculation of WTP/QALY ratio produced meaningful answers. The necessity of considering the QALY type or disease-specific QALY in estimating WTP/QALY ratio was highlighted and 1 to 3 times of gross domestic product/capita recommended by World Health Organization could potentially serve as a benchmark for threshold in this Asian context.

Entities:  

Mesh:

Year:  2011        PMID: 21224742     DOI: 10.1097/MLR.0b013e31820192cd

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  21 in total

1.  Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists.

Authors:  C Camps-Herrero; L Paz-Ares; M Codes; R López-López; A Antón-Torres; P Gascón-Vilaplana; V Guillem-Porta; A Carrato; J J Cruz-Hernández; C Caballero-Díaz; A Blasco-Cordellat; J A Moreno-Nogueira; E Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2014-06-13       Impact factor: 3.405

2.  Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.

Authors:  W Ni; Y Jiang
Journal:  Osteoporos Int       Date:  2016-08-31       Impact factor: 4.507

3.  Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting.

Authors:  Te Li; Maobai Liu; He Ben; Zhenxing Xu; Han Zhong; Bin Wu
Journal:  Clin Drug Investig       Date:  2015-06       Impact factor: 2.859

Review 4.  Potential use of NOACs in developing countries: pros and cons.

Authors:  Durga Bista; Leanne Chalmers; Luke Bereznicki; Gregory Peterson
Journal:  Eur J Clin Pharmacol       Date:  2014-05-11       Impact factor: 2.953

5.  Expected lifetime numbers, risks, and burden of osteoporotic fractures for 50-year old Chinese women: a discrete event simulation incorporating FRAX.

Authors:  Yawen Jiang; Weiyi Ni
Journal:  J Bone Miner Metab       Date:  2015-11-20       Impact factor: 2.626

6.  Economic evaluation of alternative assisted reproduction techniques in management of infertility in Greece.

Authors:  Vassilis Fragoulakis; Georgia Kourlaba; Basil Tarlatzis; Minas Mastrominas; Nikolaos Maniadakis
Journal:  Clinicoecon Outcomes Res       Date:  2012-07-12

7.  Examining Willingness-to-Pay and Zero Valuations for a Health Improvement with Logistic Regression.

Authors:  Afentoula G Mavrodi; Stavros A Chatzopoulos; Vassilis H Aletras
Journal:  Inquiry       Date:  2021 Jan-Dec       Impact factor: 1.730

8.  Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.

Authors:  Bin Wu; Jinfang Shen; Huafeng Cheng
Journal:  BMC Health Serv Res       Date:  2012-11-08       Impact factor: 2.655

9.  Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?

Authors:  Montarat Thavorncharoensap; Yot Teerawattananon; Sirin Natanant; Wantanee Kulpeng; Jomkwan Yothasamut; Pitsaphun Werayingyong
Journal:  Clinicoecon Outcomes Res       Date:  2013-01-09

10.  Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece.

Authors:  V Fragoulakis; E Kastritis; T Psaltopoulou; N Maniadakis
Journal:  Cancer Manag Res       Date:  2013-04-10       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.